Literature DB >> 28298401

Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma.

Marc de Perrot1, Zhi Dong2, Penelope Bradbury3, Demetris Patsios3, Shaf Keshavjee4, Natasha B Leighl3, Andrew Hope5, Ronald Feld3, John Cho5.   

Abstract

Tumour thickness was assessed to determine if this parameter could refine patients' selection for multimodality therapy in malignant pleural mesothelioma.We reviewed 65 consecutive treatment-naïve malignant pleural mesothelioma patients undergoing surgery for mesothelioma after radiation therapy (SMART). Total tumour thickness was determined by measuring the maximal thickness on nine predefined sectors on the chest wall, mediastinum and diaphragm.After a median follow-up of 19 months, 40 patients (62%) developed recurrence and 36 died (55%). Total tumour thickness, ranging between 2.4 and 21 cm (median 6.9 cm), correlated with tumour volume (p<0.0001, R2=0.29) and maximum standardised uptake value (p=0.006, R2=0.11). Total tumour thickness had a significant impact on overall survival and disease-free survival in univariate analysis. In multivariate analysis, total tumour thickness remained an independent predictor of survival (p=0.02, hazard ratio (HR) 1.12, 95% CI 1.02-1.23) and disease-free survival (p=0.01, HR 1.13, 95% CI 1.03-1.24) along with epithelial histologic subtype (p<0.0001, HR 0.25, 95% CI 0.13-0.50) and pN2 disease (p=0.03, HR 2.15, 95% CI 1.07-4.33). Diaphragmatic tumour thickness correlated best with time to recurrence (p=0.002, R2=0.22) and time to death (p=0.003, R2=0.2).The impact of tumour thickness on survival and disease-free survival independent of histologic subtypes and nodal disease is extremely encouraging. This parameter could potentially be used to refine the clinical staging of malignant pleural mesothelioma and optimise patient selection for radical treatment.
Copyright ©ERS 2017.

Entities:  

Mesh:

Year:  2017        PMID: 28298401     DOI: 10.1183/13993003.01428-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

Review 1.  Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma.

Authors:  Licun Wu; Marc de Perrot
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Staging in the era of international databases: documented improvements with remaining challenges.

Authors:  Robert B Cameron
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

3.  Treatment of malignant pleural mesothelioma: lessons learned and quo vadis?

Authors:  Servet Bölükbas; Michael Eberlein
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 4.  Progress in the Management of Malignant Pleural Mesothelioma in 2017.

Authors:  Amanda J McCambridge; Andrea Napolitano; Aaron S Mansfield; Dean A Fennell; Yoshitaka Sekido; Anna K Nowak; Thanyanan Reungwetwattana; Weimin Mao; Harvey I Pass; Michele Carbone; Haining Yang; Tobias Peikert
Journal:  J Thorac Oncol       Date:  2018-03-08       Impact factor: 15.609

5.  Interobserver Variability of Quantitative and Qualitative Assessment Using MRI in Malignant Pleural Mesothelioma.

Authors:  Ritu R Gill; David J Murphy; Ravi T Seethamraju; Emanuele Mazzola; Raphael Bueno; William G Richards
Journal:  Radiol Cardiothorac Imaging       Date:  2020-04-30

6.  Does size matter? -a population-based analysis of malignant pleural mesothelioma.

Authors:  Jiaxi He; Songhui Xu; Hui Pan; Shuben Li; Jianxing He
Journal:  Transl Lung Cancer Res       Date:  2020-08

7.  Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma.

Authors:  Ritu R Gill; Beow Y Yeap; Raphael Bueno; William G Richards
Journal:  J Natl Cancer Inst       Date:  2018-03-01       Impact factor: 13.506

8.  Repurposing Quinacrine for Treatment of Malignant Mesothelioma: In-Vitro Therapeutic and Mechanistic Evaluation.

Authors:  Nishant S Kulkarni; Bhuvaneshwar Vaidya; Vineela Parvathaneni; Debarati Bhanja; Vivek Gupta
Journal:  Int J Mol Sci       Date:  2020-08-31       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.